Our capabilities and experience

Read more about how we help manage complex clinical research across many therapeutic areas worldwide.

  • Resource Type

  • Services

  • Indication

  • Reset filters
Found 50 Results
Page 3 of 5
Video

Takeaways From the PREVAIL Network Trip

Upon their return from visiting Liberia and the PREVAIL network sites, we asked a team of FHI Clinical experts what they learned during their time in the country.


Video

Purpose of the Visit to the PREVAIL Network in Liberia

In the fall of 2021, a small team from FHI Clinical headed to Liberia to meet the FHI Clinical PREVAIL network team. Watch this video to learn more about the purpose and goals of their trip.


Video

We Are Mission Driven

Our team is caring, passionate and working towards the same goal: to address unmet research needs and achieve maximum social impact by supporting the development of life-saving vaccines and medicines. Watch the video to learn why our team thinks being mission-driven makes FHI Clinical a special place to work.


Video

We Partner With Our Sites

Our site managers partner with study sites to ensure their success throughout the length of the project. This can include training and re-training for procedures, processes, protocol, ICH GCP, data management, informed consent and more.


Video

How We Build Research Capacity

We believe that building and sustaining research capacity, particularly in resource-limited, research-naïve areas, will help address public health issues around the globe. Watch the video to learn how our teams support sites to develop sustainable research capacity and produce high-quality study data. In addition, we work with regional institutions to establish networks of research-ready sites that focus on local health and research priorities.


Indication Overview

Coronaviruses Fact Sheet

Discovered in the 1960s, coronaviruses (CoV) are a large group of RNA viruses in the family Coronaviridae that cause disease in humans and animal species. Human illness includes respiratory infections that range from the common cold to viral (direct) or bacterial (indirect) pneumonia and are especially serious in infants and at-risk adults. There are seven known coronavirus types/strains.


Brochure

About the PREVAIL Network

The Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) network was established through a partnership between local Liberian and international partners, including the U.S. National Institutes of Health, World Health Organization and FHI Clinical, to provide sustainable research infrastructure to address diseases of public health importance.


Video

Celebrating Our 2-Year Anniversary

We’re proud of our progress and remain committed to and passionate about our mission-driven work globally.


Case Study

Phase II Trial of a Chikungunya Vaccine in the Caribbean

The study team maintained a 91% retention rate in a study of a Chikungunya virus (CHIKV) vaccine, despite study disruptions due to natural disasters, including Hurricane Maria, and political unrest near the sites in five Caribbean countries in a CHIKV endemic region.


e-Book

How Can We Streamline the Vaccine Development Process?

To address the urgency of vaccine development during a pandemic, innovative strategies are implemented across study design, regulatory processes, recruitment process and more. In this e-book, we describe some of those innovations and argue for incorporating these into the fabric of clinical trials — to establish a “new normal.”